MedTrace Logo

Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial

NCT04330690 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 2900

Last updated 2023-10-13

No results posted yet for this study

Summary

This study is an adaptive, randomized, open-label, controlled clinical trial, in collaboration with countries around the world through the World Health Organization.

Conditions

Interventions

DRUG

Artesunate

2.4 mg/kg at 0 hours, 12 hours, 24 hours, and then daily for a total of 7 days plus standard of care

DRUG

Imatinib

400 mg enterally daily for 14 days plus standard of care

DRUG

Infliximab

5 mg/kg IV given one time, over 2 hours plus standard of care

DRUG

Dexamethasone

6 mg IV/oral for a further five days, followed by a five day taper of 4 mg x 2 days and 2 mg x 3 days, for a total 20 day steroid course. If randomized to standard of care, discontinue the corticosteroid on day 10

DRUG

LSALT Peptide

5 mg , 2 hour IV infusion once daily for up to 14 consecutive days

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • Apotex Inc.

    collaborator INDUSTRY

  • World Health Organization

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Arch Biopartners Inc.

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Srinivas Murthy, MD · Provincial Health Services Authority

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-18
Primary Completion
2024-03-10
Completion
2024-05-18

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04330690 on ClinicalTrials.gov